Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Chronic lymphocytic leukemia Alemtuzumab

Infection risk In a study of consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia, alemtuzumab was associated with five deaths resulting from infections (viral, Listeria meningitis and Legionella, cytomegalovirus, and Pneumocystis jirovedi pnemnonia), which occurred up to 7 months after the last administration [bS "]. [Pg.586]

Alemtuzumab is the antibody to the CD52 receptor present on B and T lymphocytes. The pharmacokinetics of alemtuzumab demonstrate a terminal half-life of 7 days. Alemtuzumab has shown clinical activity in the treatment of chronic lymphocytic leukemia. Severe and prolonged (6 months) immunosuppression may result, which necessitates prophylaxis with cotrimox-azole and antivirals to prevent opportunistic infections. [Pg.1294]

CamPath Alemtuzumab ILEX, Pharmaceuticals Millenium, Cambrige, MA Anti-CD52 Chronic lymphocytic leukemia 2001... [Pg.580]

Alemtuzumab Campath Humanized IgGltc anti-CD52 Chronic lymphocytic leukemia 2001 United States... [Pg.114]

Alemtuzumab is a recombinant DNA-derived humanized monoclonal antibody used in the treatment of chronic lymphocytic leukemia and T-cell lymphoma. It targets CD52, a protein present on the surface of mature lymphocytes. Alemtuzumab has been associated with infusion-related events including hypotension, rigors, fever, shortness of breath, bron-chospasm, chills, and/or rash. Also reported were syncope, pulmonary infiltrates, cardiac arrhythmias, myocardial infarction and cardiac arrest. [Pg.461]

Pharmacokinetics The pharmacokinetic profile of alemtuzumab was studied in a rising-dose trial in non-Hodgkin s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Campath was administered once weekly for a maximum of 12 weeks. Following intravenous infusions over a range of doses, the maximum serum concentration (C ax) and the area under the curve (AUC) showed relative dose pro-... [Pg.300]

Mone AP, Cheney C, Banks AL et al. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia... [Pg.227]

Keating M, Coutre S, Rai K et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 2004 4 220-227. [Pg.227]

Montillo M, Schinkoethe T, Elter T. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome. Cawcer/wvext 2005 23 488-496. [Pg.227]

Lin IS, Flinn IW, Modali R et al. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. B/ooii2005 105 289-291. [Pg.229]

NK cells, monocytes, macrophages, and a small population of granulocytes. Currently, alemtuzumab is approved for the treatment of -cell chronic lymphocytic leukemia in patients who have been treated with alkylating agents and have failed fludarabine therapy. Alemtuzumab appears to deplete leukemic and normal cells by direct antibody-dependent lysis. Patients receiving this antibody become lymphopenic and may also become neutropenic, anemic, and thrombocytopenic. As a result patients should be closely monitored for opportunistic infections and hematologic toxicity. [Pg.1197]

Rai KR, Freter CD, Merrier RJ, Cooper MR. 2002. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received Fludarabine. J Clin Oncol. 20 3891-3897. [Pg.125]

Rawstron AC, Kennedy B, Moreton P, Dickinson AJ, et al. 2004. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood. 103 2027-2031. [Pg.125]

Alemtuzumab [Campath] Chronic lymphocytic leukemia Blood disorders [anemia, leukopenia, neutropenia, thrombocytopenia] chest pain, dyspnea infection nausea... [Pg.578]

Alemtuzumab Campath B-cell chronic lymphocytic leukemia (B-CLL) 2001... [Pg.88]

Campath / MabCampath/ Alemtuzumab Immunoglobulin G1 Chronic lymphocytic leukemia... [Pg.396]

Alemtuzumab (campath-lH) is a humanized monoclonal antibody specific for the CDw52 antigen, present on cell membranes of lymphocytes and monocytes. It has been used for treatment of patients with rheumatoid arthritis and vasculitis, is being investigated for the treatment of chronic lymphocytic leukemia, and has been used to deplete circulating lymphocytes in patients with multiple sclerosis (1). In 2001, alemtuzumab was approved in Europe for the treatment of chronic B cell lymphocytic leukemia that had been treated previously with alkylating agents and was refractory to fludarabine (2). It has also been used for induction of immunosuppression/tolerance in liver transplant recipients (3,4) and kidney/pancreas transplant recipients (5). [Pg.71]

Reactivation of cytomegalovirus is a frequent complication during treatment with alemtuzumab in patients with chronic lymphocytic leukemia (10), and other organisms are occasionally described. [Pg.71]

Robak T. Alemtuzumab in the treatment of chronic lymphocytic leukemia. BioDrugs 2005 19(l) 9-22. [Pg.71]

Laurenti L, Piccioni P, Cattani P, Cingolani A, Efremov D, Chiusolo P, Tarnani M, Fadda G, Sica S, Leone G. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia incidence and treatment with oral ganciclovir. Haematologica 2004 89(10) 1248-52. [Pg.72]

Cavalli-Bjorkman N, Osby E, Lundin J, Kalin M, Osterborg A, Gruber A. Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B cell chronic lymphocytic leukemia. Med Oncol 2002 19(4) 277-80. [Pg.72]

Abciximab Prevention ot ischemic cardiac complications during percutaneous coronary interventions short-term prevention ot myocardial infarction Atelimomab Treatment ot sepsis Alemtuzumab Chronic lymphocytic leukemia Apolizumab Chronic lymphocytic leukemia Basiliximab Prevention ot acute renal allograft rejection Clenoliximab Rheumatoid arthritis Daclizumab Prevention ot acute renal allograft rejection Edrecolomab Adjuvant therapy tor cancer after colorectal surgery... [Pg.2381]

Alemtuzumab (Campath) Anti-CD52 Ab - B-cell chronic lymphocytic leukemia - Preconditioning regimen for bone marrow and renal transplantation -HUS -Acute renal failure - Acute humoral rejection 98,99,101... [Pg.684]

Alemtuzumab CD52 Normal and malignant B-lymphocytes, T cells, NK cells, monocytes, macrophages, platelets (not hematopoietic stem cells) Chronic lymphocytic leukemia Hypersensitivity and infusion related reactions, profound immunosuppression... [Pg.156]

GL is a 56-year-old man with refractory chronic lymphocytic leukemia. He has failed prior therapy with fludarabine and chlorambucil. His oncologist wishes to start treatment with alemtuzumab. Which of the following precautions should be undertaken prior to starting this therapy ... [Pg.157]

O Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003 98 2657-2663. [Pg.2524]

Mabcampath (EU) or Campath (US) (Alemtuzumab humanized mAb directed against CD52 surface antigen of B lymphocytes) Millennium and ILEX (EU), and Ber-lex, ILEX Oncology and Millennium Pharmaceuticals (US) chronic lymphocytic leukemia 2001 (EU and US)... [Pg.38]

Alemtuzumab Campath-IH Schering humanized mAb CD52 chronic lymphocytic leukemia 2001 IgGl 2%... [Pg.1151]

Hale, G., Rebello, P., Brettman, L. R., Fegan, C., Kennedy, B., Kimby, E., Leach, M., Lundin, J., Mellstedt, H., Moreton, P., Rawstron, A. C., Waldmann, H., Osterborg, A., Hillmen, P. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004, 104, 948-955. [Pg.1179]

Alemtuzumab CD52 B-cell chronic lymphocytic leukemia Infections, hematologic toxicity, infusion reactions, hypersensitivity... [Pg.455]

Campath , alemtuzumab, a humanized monoclonal antibody used in the treatment of B-cell chronic lymphocytic leukemia. The campath-IH family of antibodies recognize an abundant glycoprotein on virtually all human lymphocytes. Campath (Millenium Pharm. Inc. and ILEX Oncology Inc.) was registered in the USA in 2001 [M. A. van Dijk, J. G. J. van den Winkel, Curr. Opin. Chem. Biol. 2001, 5, 368]. [Pg.62]

Hillmen P et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology 2007 25 5616-5623. [Pg.359]

See other pages where Chronic lymphocytic leukemia Alemtuzumab is mentioned: [Pg.722]    [Pg.222]    [Pg.118]    [Pg.1349]    [Pg.71]    [Pg.178]    [Pg.189]    [Pg.1156]    [Pg.54]    [Pg.919]    [Pg.795]    [Pg.15]    [Pg.341]    [Pg.419]   
See also in sourсe #XX -- [ Pg.223 ]



SEARCH



Alemtuzumab

Chronic lymphocytic leukemia

Leukemia chronic

Lymphocyte leukemia

Lymphocytic leukemia

© 2024 chempedia.info